TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10362176

Group type: EXPERIMENTAL
Intervention: Induction of labor with oxytocin
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Induction of labor with prostaglandins
Number of subjects: 5041

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Delivery in Israel
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Delivery in Australia
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Labor lasting more than 12 hours
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Labor lasting 6-12 hours
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Previous cesarean delivery
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Clinical chorioamnionitis
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Internal fetal heart rate monitoring
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Birth weight of at least 4000 g
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Maternal age of at least 35 years
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Latent period of at least 12 hours
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: Meconium staining
Number of subjects: 5041
Study: 8746573

Group type: EXPERIMENTAL
Intervention: Sutureless scleral tunnel frown incision
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scleral tunnel frown incision with a horizontal suture
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scleral tunnel frown incision with both a horizontal and a running suture
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Posterior limbal acute beveled cataract incision with a running suture
Number of subjects: 200
Study: 2183645

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) - 1 g intravenously
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 18
Study: 7453160

Group type: EXPERIMENTAL
Intervention: Isotonic training (IT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Isokinetic training (IK)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 30244533

Group type: EXPERIMENTAL
Intervention: O‐SES (Orsiro sirolimus‐eluting stent)
Number of subjects: 2525

Group type: COMPARATOR
Intervention: N‐BES (Nobori biolimus‐eluting stent)
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: O‐SES
Number of subjects: 2525

Group type: COMPARATOR
Intervention: N‐BES
Number of subjects: 2525
Study: 29143428

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 μg/day + Calcium 500 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo + Calcium 500 mg/day
Number of subjects: 95
Study: 27764706

Group type: EXPERIMENTAL
Intervention: Pregabalin for 14 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pregabalin for 1 day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 105
Study: 24559249

Group type: EXPERIMENTAL
Intervention: Standardised cigarette packaging
Number of subjects: 98

Group type: COMPARATOR
Intervention: Branded cigarette packaging
Number of subjects: 98

Group type: COMPARATOR
Intervention: Own cigarette package
Number of subjects: 98
Study: 22460260

Group type: EXPERIMENTAL
Intervention: Training on ethylene‐vinyl acetate (EVA) bench model with feedback of instructors
Number of subjects: 16

Group type: COMPARATOR
Intervention: Faculty-directed training based on books and instructional videos (Control)
Number of subjects: 16
Study: 20487610

Group type: EXPERIMENTAL
Intervention: Household symptom screening and spot sputum collection (Arm 1)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Distribution of an educational pamphlet (Arm 2)
Number of subjects: 193
Study: 18790208

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 118
Study: 16911730

Group type: EXPERIMENTAL
Intervention: Cue exposure therapy (CET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment attentional bias
Number of subjects: 0
Study: 12021419

Group type: EXPERIMENTAL
Intervention: Exercise program (12 months of home‐based exercise counseling, at least four exercise sessions per week, for at least 30 minutes per session)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention control (nutrition education)
Number of subjects: 100
Study: 10588819

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.3 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study: 8738728

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (40 mg, orally; n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study: 1820892

Group type: EXPERIMENTAL
Intervention: Oral administration of 2 mg idaverine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 mg idaverine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 2 mg idaverine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Idaverine (all doses)
Number of subjects: 12
Study: 6357018

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing (IPPB) therapy
Number of subjects: 985

Group type: COMPARATOR
Intervention: Compressor nebulizer therapy
Number of subjects: 985
Study: 29362242

Group type: EXPERIMENTAL
Intervention: Alternative Grading of Recommendations Assessment, Development and Evaluation (GRADE) SoF table
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based Practice Center SoF table
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current GRADE SoF table
Number of subjects: 0
Study: 27157843

Group type: EXPERIMENTAL
Intervention: Topical bimatoprost ocular insert
Number of subjects: 130

Group type: COMPARATOR
Intervention: Timolol (0.5% solution) eye drops
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Bimatoprost ocular insert
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Bimatoprost ocular insert and Timolol
Number of subjects: 130
Study: 25628069

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (preserved LV function)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Heart failure patients (without CRT)
Number of subjects: 37
Study: 23808510

Group type: EXPERIMENTAL
Intervention: Group A (alkalinised lignocaine)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group L (lignocaine)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Group S (control, normal saline)
Number of subjects: 300
Study: 21088639

Group type: EXPERIMENTAL
Intervention: Educational video on child passenger safety
Number of subjects: 139

Group type: COMPARATOR
Intervention: Comparison group (no video)
Number of subjects: 139
Study: 18988910

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1644
Study: 16479368

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 0
Study: 14967869

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) 1.0 g x kg body mass(-1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 9
Study: 11069375

Group type: EXPERIMENTAL
Intervention: Adjuvant mitozantrone chemotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 96
Study: 8686962

Group type: EXPERIMENTAL
Intervention: 30 mg 5‐ISMN once daily for one week followed by 60 mg 5‐ISMN once daily for one week
Number of subjects: 89

Group type: COMPARATOR
Intervention: 60 mg 5‐ISMN once daily for two weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both dosage regimens
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Starting on a low dosage
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 89
Study: 1283656

Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Histamine release test
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DBPCFC with fresh codfish
Number of subjects: 37
Study: 4019261

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31200819

Group type: EXPERIMENTAL
Intervention: Chemotherapy (first line)
Number of subjects: 111
Study: 29733329

Group type: EXPERIMENTAL
Intervention: CHX-containing dressing
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 57
Study: 27543984

Group type: EXPERIMENTAL
Intervention: Unblinded cytology review
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Unblinded cytology review in HPV-negative women
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Unblinded cytology review in HPV 16+/HPV 18+ women
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Unblinded cytology review with cotesting
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Unblinded cytology review with HPV primary screening
Number of subjects: 428
Study: 26448164

Group type: EXPERIMENTAL
Intervention: Cash reward of 150 for achieving target weight
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Cash reward of 300 for achieving target weight
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 700
Study: 22652402

Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given concurrently
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given sequentially (21 days later)
Number of subjects: 282

Group type: COMPARATOR
Intervention: H1N1pdm09 vaccine alone
Number of subjects: 282
Study: 20421240

Group type: EXPERIMENTAL
Intervention: Center-based falls prevention service
Number of subjects: 107

Group type: COMPARATOR
Intervention: Domiciliary falls prevention service
Number of subjects: 107
Study: 18586189

Group type: EXPERIMENTAL
Intervention: Hyaluronidase injection (n = 71)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No injection (control group, n = 68)
Number of subjects: 139
Study: 16260247

Group type: EXPERIMENTAL
Intervention: Educational Jeopardy style game
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard lecture
Number of subjects: 104
Study: 11906779

Group type: EXPERIMENTAL
Intervention: Combined vaccination (DTPw-HB/Hib)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Separate injection vaccination (DTPw-HB and Hib)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 400
Study: 10422951

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg for induction followed by propofol 75‐150 microg x kg(‐1) x min(‐1) for maintenance
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sevoflurane 1‐2% with N2O 67% in oxygen for maintenance
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sevoflurane in combination with N2O 67% in oxygen for induction and maintenance
Number of subjects: 104
Study: 7669461

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 30
Study: 1886362

Group type: EXPERIMENTAL
Intervention: Posterior fixation alone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional symmetrical recessions of the medial recti
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Anterior medial tenotomies
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stretch effect
Number of subjects: 79
Study: 272207

Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone with anthracycline
Number of subjects: 137

Group type: COMPARATOR
Intervention: Vincristine and prednisone without anthracycline
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Asparaginase consolidation and CNS prophylaxis with cranial irradiation and intrathecal methotrexate
Number of subjects: 137
Study: 31842977

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 500

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 500
Study: 28143471

Group type: EXPERIMENTAL
Intervention: Systemic Manual Acupuncture (MA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Distal Electroacupuncture (DE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Periauricular Electroacupuncture (PE)
Number of subjects: 39
Study: 25762651

Group type: EXPERIMENTAL
Intervention: 12-hour nicotine deprivation
Number of subjects: 54

Group type: COMPARATOR
Intervention: smoked as usual
Number of subjects: 54
Study: 23356491

Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SV (Stanford V; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 44
Study: 17502874

Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Lean fish (3 x 150 g portions of cod/week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fatty fish (3 x 150 g portions of salmon/week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fish oil (DHA/EPA capsules, no seafood)
Number of subjects: 324
Study: 15539546

Group type: EXPERIMENTAL
Intervention: Mixed-model analyses of covariance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraclass correlations (ICCs) estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulae for adjustments for fixed and time-varying covariates
Number of subjects: 0
Study: 11198784

Group type: EXPERIMENTAL
Intervention: Fibernat (dietary fiber preparation)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 9107166

Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual nitroglycerin administration
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8473716

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nefazodone 400 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All active compounds (Nefazodone and Imipramine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day with alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg/day with alcohol
Number of subjects: 12
Study: 2951158

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg thrice daily
Number of subjects: 17
Study: 30882553

Group type: EXPERIMENTAL
Intervention: DrinkWise (e‐SBI)
Number of subjects: 185
Study: 28938434

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin clamp studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat dietary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: T2D condition
Number of subjects: 0
Study: 26808782

Group type: EXPERIMENTAL
Intervention: Gait observation (viewing videos of healthy and parkinsonian gait)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Landscape observation (viewing videos of moving water)
Number of subjects: 23
Study: 25516025

Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 129
Study: 22455544

Group type: EXPERIMENTAL
Intervention: Integrative care (IC) plus usual care (UC)
Number of subjects: 20
Study: 18948027

Group type: EXPERIMENTAL
Intervention: Hemospan (MP4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 260/0.45 (HES 260/0.45)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES 130/0.4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 0
Study: 17321924

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg given intravenously over 10 minutes, 0.4 microg.kg‐1.h‐1, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg.kg‐1 bolus, 1 microg.kg‐1.h‐1, n=20)
Number of subjects: 40
Study: 15343554

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the quadriceps femoris
Number of subjects: 38

Group type: COMPARATOR
Intervention: Arthritis education-only group
Number of subjects: 38
Study: 12243105

Group type: EXPERIMENTAL
Intervention: 6-week basic training
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 8-week basic plus booster training
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Follow-up with funding and training organizations
Number of subjects: 76
Study: 9690592

Group type: EXPERIMENTAL
Intervention: Needle-through-needle technique (SST)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Double-segment technique (DST)
Number of subjects: 120
Study: 8600747

Group type: EXPERIMENTAL
Intervention: Universal ankle training brace
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kallassy ankle training brace
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Air-Stirrup ankle training brace
Number of subjects: 12

Group type: COMPARATOR
Intervention: No brace (control)
Number of subjects: 12
Study: 2504072

Group type: EXPERIMENTAL
Intervention: Psomaglobin (Pseudomonas hyperimmune globulin)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 31911348

Group type: EXPERIMENTAL
Intervention: 50 mg of the opioid receptor antagonist naltrexone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 159
Study: 29779182

Group type: EXPERIMENTAL
Intervention: Locator prosthesis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceramic/electroplated double-crown prosthesis
Number of subjects: 12
Study: 27826127

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 80μg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide 20μg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26115878

Group type: EXPERIMENTAL
Intervention: ACEi plus exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic plus exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AT1 receptor antagonist plus exercise training
Number of subjects: 0
Study: 23332727

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 7200
Study: 21744082

Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: L-BLP25 plus BSC (stage IIIB loco-regional subgroup)
Number of subjects: 171

Group type: COMPARATOR
Intervention: BSC alone (stage IIIB loco-regional subgroup)
Number of subjects: 171
Study: 19183833

Group type: EXPERIMENTAL
Intervention: Non-stented internal biliary drainage (group I)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stented external biliary drainage (group E)
Number of subjects: 46
Study: 17115612

Group type: EXPERIMENTAL
Intervention: Extra Erbisol
Number of subjects: 0
Study: 15055504

Group type: EXPERIMENTAL
Intervention: Floor mat
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Insoles
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wood-block floor
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Insoles and mat conditions
Number of subjects: 11
Study: 11368808

Group type: EXPERIMENTAL
Intervention: Alarmed vial
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-alarmed vial (Control)
Number of subjects: 100
Study: 9227540

Group type: EXPERIMENTAL
Intervention: 10 ml/kg body weight of 0.5 M racemic sodium lactate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14
Study: 8435738

Group type: EXPERIMENTAL
Intervention: Pelvic floor training programme (5 sessions, weekly, supervised by physiotherapists)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Surgery (dissection and removal of the deep dorsal vein of the penis and its tributaries)
Number of subjects: 150
Study: 2956873

Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo, given 3 times daily for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg and 100 mg, given 3 times daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enoximone 150 mg, given 3 times daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily
Number of subjects: 16
Study: 30285645

Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (60 min, twice a week for 12 months)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy
Number of subjects: 600
Study: 27266821

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Paracardial adipose tissue (PAT) volume
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Mean attenuation of EAT
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Mean attenuation of PAT
Number of subjects: 467
Study: 24033362

Group type: EXPERIMENTAL
Intervention: BisGMA-based composite restorations
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: UDMA-based compomer restorations
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BisGMA-based restorations
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (Amalgam treatment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Greater treatment levels
Number of subjects: 59
Study: 23168823

Group type: EXPERIMENTAL
Intervention: Citicoline (2000 mg daily for 90 days)
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 1213
Study: 20693804

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 652

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 652